South San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Nkarta Therapeutics is raising $114,636,678.00 in a new round of investment. Sources indicate as part of senior management President, Paul Hastings played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Nkarta Therapeutics

Nkarta was founded on the proprietary, robust and well characterized natural killer (NK) cell expansion technology pioneered by Dario Campana. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. Nkarta is combining its NK expansion platform technology with proprietary cell engineering technologies to build differentiated autologous and allogeneic cell therapy candidates for the treatment of cancer.

To learn more about Nkarta Therapeutics, visit http://www.nkartatx.com/

Contact:
Paul Hastings, President
650-215-0385
phastings@nkartatx.com
https://www.linkedin.com/in/paul-hastings-25365a6/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved